Drug Database
Back to search

Netherlands· NL-ee04dfc4cba7

Jyseleca 200 mg, filmomhulde tabletten

A filgotinib product containing filgotinibmaleaat, registered in Netherlands by Alfasigma S.p.A.. The same ATC class is registered in 10 of our 19 countries.

ATC L04AF04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedJyseleca 200 mg, filmomhulde tablettenATCL04AF04REGISTER NO.NL-ee04dfc4cba7PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about filgotinibmaleaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Filgotinib is registered in 10 of 19 countries.

Countries holding a registration under ATC L04AF04 (filgotinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search filgotinib products by name

Filgotinib · ATC L04AF04

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
FILGOTINIBMALEAAT
Manufacturer
Alfasigma S.p.A.
Country
Netherlands (NL)
ATC code
L04AF04
ATC class
Filgotinib
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/20/1480

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Filgotinib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All filgotinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Jyseleca
  • Liechtenstein · Jyseleca
  • Norway · Jyseleca

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ce3c2e0d-dbf7-4841-ad40-5c22d31a0130
GET /v1/drugs/ce3c2e0d-dbf7-4841-ad40-5c22d31a0130?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Filgotinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp125423",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "FUMAARZUUR (E 297)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYVINYLALCOHOL (E 1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)",
    "ZETMEEL, GEPREGELATINEERD"
  ],
  "substances": [
    "FILGOTINIBMALEAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2020/09/24",
  "procedure_number": "EMEA/H/C/005113",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/20/1480",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about filgotinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console